

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
21 September 2023 (21.09.2023)



(10) International Publication Number
WO 2023/178144 A3

(51) International Patent Classification:

C07H 15/00 (2006.01) A61K 47/54 (2017.01)
C12N 15/113 (2010.01)

(21) International Application Number:

PCT/US2023/064384

(22) International Filing Date:

15 March 2023 (15.03.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/320,431	16 March 2022 (16.03.2022)	US
63/354,359	22 June 2022 (22.06.2022)	US
63/430,542	06 December 2022 (06.12.2022)	US

Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))

Published:

— with international search report (Art. 21(3))
— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
— with sequence listing part of description (Rule 5.2(a))

(88) Date of publication of the international search report:

26 October 2023 (26.10.2023)

(71) Applicant: **EMPIRICO INC.** [US/US]; 4660 La Jolla Village Drive, Suite 100, San Diego, California 92122 (US).

(72) Inventors: **WAKEFIELD, Darren H.**; 4660 La Jolla Village Drive, Suite 100, San Diego, California 92122 (US). **ROZEMA, David**; 4660 La Jolla Village Drive, Suite 100, San Diego, California 92122 (US). **GOTTESMAN, Omri**; 4660 La Jolla Village Drive, Suite 100, San Diego, California 92122 (US).

(74) Agent: **HECKER, Peter A.**; Wilson Sonsini, 650 Page Mill Road, Palo Alto, California 94304 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: GALNAC COMPOSITIONS FOR IMPROVING SIRNA BIOAVAILABILITY

(57) Abstract: Provided herein, are compositions comprising GalNac moieties that may be conjugated to an oligonucleotide. The oligonucleotide may be a small interfering RNA or an antisense oligonucleotide. Also provided herein are methods of treatment that include administering the composition to a subject.

WO 2023/178144 A3